Children's Hospital at Montefiore NYC
"Overcoming History for a Brighter Tomorrow"
Our Sickle Cell Disease population is vast here at The Children’s Hospital at Montefiore. Traditionally, HSCT has been very difficult for this patient population because of a lack of appropriate donors and because historically the toxicities of stem cell transplantation for non-malignant hemoglobinopathies have been thought to be too significant to justify the risk. This has pushed us to learn about ways to overcome these challenges to provide life-changing opportunities to our patients who otherwise succumb to their debilitating disease.
The development of haploidentical transplants has made a donor available to almost every patient who needs a transplant, and the development of reduced intensity conditioning regimens makes the procedure acceptably safe. The future is also bright for solid tumor patients, where haploidentical transplantation can provide a non-exhausted, unedited immune system to combat chemotherapy-resistant disease. We intend to be at the forefront of that movement to give our patients an even greater chance at disease eradication. We are striving to bring the newest, greatest, and safest treatments to our underserved patient population. We want to help bring change to their lives for the best, in hopes for a brighter tomorrow.